Lung NeoplasmsNCT01413737
Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days
An observational study of Lung Neoplasms, run by Norwegian University of Science and Technology at 2 sites in Norway.
Trial summary
This is a retrospective, descriptive analysis of (1) 30 day postoperative results of surgery for lung cancer, (2) 30 day outcome predictors - compared to an earlier similar study in the same hospital (St Olav University Hospital, Trondheim, Norway). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Lung Neoplasms
- How many people
- 148 participants
- Where
- 2 sitesNorway
- Study dates
- Jan 2002to Dec 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: lung cancer patients after surgery at St Olavs University Hospital
Who may be able to join
- Lung cancer patients after surgery in 2002-2004 at dept for Heart and Lung Surgery, St.Olavs University Hospital, Trondheim, Norway.
Who cannot join
- Carcinoid tumor, small-cell lung cancer, lung metastases
Trial locations and contacts
2 sites in 1 country.
About this study
This is a retrospective, descriptive analysis of (1) 30 day postoperative results of surgery for lung cancer, (2) 30 day outcome predictors - compared to an earlier similar study in the same hospital (St Olav University Hospital, Trondheim, Norway).
- Conditions
- Lung Neoplasms
- Medical subject headings
- Lung Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2011 (estimated)
- Study startJan 2002
- Primary completionDec 2006
- Study completionDec 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Lung NeoplasmsStudies of the same condition, open and under way.
- More trials run by Norwegian University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 148 participants (actual)
Sponsor and investigators
- Lead sponsor
- Norwegian University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rune Haaverstad, Ph.D, Study chair, National Taiwan Normal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01413737
- Sponsor's protocol ID
- 4.2005.1826
- Status last verified
- Mar 2017
- First submitted
- 22 Sep 2005
- Last updated
- 10 Mar 2017
- Results posted
- No
Publications
Hjelde H, Sundstrom S, Odegard A, Hatlinghus S, Abusland AB, Haaverstad R. [Recurrence and survival after surgical treatment of lung cancer]. Tidsskr Nor Laegeforen. 2010 Jan 14;130(1):25-8. doi: 10.4045/tidsskr.09.0689. Norwegian.
PubMed 20094119Roth K, Nilsen TI, Hatlen E, Sorensen KS, Hole T, Haaverstad R. Predictors of long time survival after lung cancer surgery: a retrospective cohort study. BMC Pulm Med. 2008 Oct 27;8:22. doi: 10.1186/1471-2466-8-22.
PubMed 18954454
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days
- ClinicalTrials.gov ID
- NCT01413737
- Acronym / sponsor ID
- 4.2005.1826
- Conditions
- Lung Neoplasms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 148 participants (actual)
- Lead sponsor
- Norwegian University of Science and TechnologyUniversity, hospital or other
- Study start
- Jan 2002 (actual)
- Primary completion
- Dec 2006 (actual)
- Study completion
- Dec 2006 (actual)
- First posted
- 10 Aug 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective, descriptive analysis of (1) 30 day postoperative results of surgery for lung cancer, (2) 30 day outcome predictors - compared to an earlier similar study in the same hospital (St Olav University Hospital, Trondheim, Norway).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- lung cancer patients after surgery at St Olavs University Hospital
Key inclusion criteria (1 listed)
- Lung cancer patients after surgery in 2002-2004 at dept for Heart and Lung Surgery, St.Olavs University Hospital, Trondheim, Norway.
Key exclusion criteria (1 listed)
- Carcinoid tumor, small-cell lung cancer, lung metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2017.
- Results publication: PubMed 20094119Hjelde H, Sundstrom S, Odegard A, Hatlinghus S, Abusland AB, Haaverstad R. [Recurrence and survival after surgical treatment of lung cancer]. Tidsskr Nor Laegeforen. 2010 Jan 14;130(1):25-8. doi: 10.4045/tidsskr.09.0689. Norwegian.
- Results publication: PubMed 18954454Roth K, Nilsen TI, Hatlen E, Sorensen KS, Hole T, Haaverstad R. Predictors of long time survival after lung cancer surgery: a retrospective cohort study. BMC Pulm Med. 2008 Oct 27;8:22. doi: 10.1186/1471-2466-8-22.
Related trials for Lung Neoplasms
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rune Haaverstad, Ph.D study chair
National Taiwan Normal University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Neoplasms, run by Norwegian University of Science and Technology at 2 sites in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01413737, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2017.